biological source
mouse
Quality Level
conjugate
unconjugated
antibody form
ascites fluid
antibody product type
primary antibodies
clone
BP18, monoclonal
species reactivity
mouse, human
manufacturer/tradename
Upstate®
technique(s)
immunoprecipitation (IP): suitable, western blot: suitable
isotype
IgM
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... TP53BP1(7158)
mouse ... Trp53Bp1(27223)
General description
~250kDa
Immunogen
Mix of three GST fusion proteins corresponding to residues 1-337, 338-671, and 1331-1664, respectively, of human 53BP1
Application
Detect 53BP1 with Anti-53BP1 Antibody, clone BP18 (Mouse Monoclonal Antibody), that has been shown to work in IP & WB.
Research Category
Epigenetics & Nuclear Function
Epigenetics & Nuclear Function
Research Sub Category
Transcription Factors
Transcription Factors
Biochem/physiol Actions
53BP1
Physical form
Ascites
mouse ascites IgM containing 0.05% sodium azide and 30% glycerol
Preparation Note
2 years at -20°C
Analysis Note
routinely evaluated by immunoblot on whole cell lysates from HeLa cells
Legal Information
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
存储类别
10 - Combustible liquids
wgk
WGK 1
Irene M Ward et al.
Molecular and cellular biology, 23(7), 2556-2563 (2003-03-18)
53BP1 is a p53 binding protein of unknown function that binds to the central DNA-binding domain of p53. It relocates to the sites of DNA strand breaks in response to DNA damage and is a putative substrate of the ataxia
Maria Pinkerneil et al.
Molecular cancer therapeutics, 15(2), 299-312 (2016-01-17)
Class I histone deacetylases HDAC1 and HDAC2 contribute to cell proliferation and are commonly upregulated in urothelial carcinoma. To evaluate whether specific inhibition of these enzymes might serve as an appropriate therapy for urothelial carcinoma, siRNA-mediated knockdown and specific pharmacologic
Maria Pinkerneil et al.
Targeted oncology, 11(6), 783-798 (2016-06-03)
Targeting of class I histone deacetylases (HDACs) exerts antineoplastic actions in various cancer types by modulation of transcription, upregulation of tumor suppressors, induction of cell cycle arrest, replication stress and promotion of apoptosis. Class I HDACs are often deregulated in
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 05-725 | 04053252274343 |